2407 (2407) Fair Value & Analysis

Healthcare · Market cap HK$736M

2 2407 2407 · HK

PriceHK$5.00

Fair ValueHK$14.30

Upside+186.0%

Quality45/100

Watch 2407 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$10.21 – HK$18.71

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price +1.6% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$4.67 – HK$9.85 · fair‑value band HK$10.21 – HK$18.71 · the HK$5.00 price screens below the HK$14.30 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2407 (2407) currently trades at HK$5.00, while our model-based Fair Value estimate is HK$14.30 — implying the stock looks roughly 186.0% undervalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2407 generated revenue of HK$1.4B at a net margin of 7.0%. Revenue declined 7.5% year over year. It earns a return on equity of 5.6%. Net debt stands at HK$66.4M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.4B

Revenue growth (YoY) -7.5%

Net margin 7.0%

Return on equity 5.6%

Free cash flow HK$110M FY2025

P/E ratio 6.6

More key figures

Operating margin 6.5%

EPS (TTM) HK$0.2600

EPS growth (YoY) -6.8%

Net debt HK$66.4M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2407 reported revenue of HK$1.4B in FY2025 versus HK$1.3B in FY2021, a compound +1.5%/yr. Reported net income was HK$96.2M in FY2025.

Revenue +1.5%/yr

FY21 HK$1.3B

FY22 HK$1.3B

FY23 HK$1.4B

FY24 HK$1.4B

FY25 HK$1.4B

Net income

FY21 −HK$190M

FY22 −HK$350M

FY23 HK$174M

FY24 HK$92.4M

FY25 HK$96.2M

Is 2407 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,228 MXN	-23%
Abbott Laboratories, ABTT34	R$37.76	R$6.34	-83%
Stryker Corporation S1YK34	R$77.83	R$8.47	-89%
Medtronic plc MDT	$80.25	$74.40	-7%
Boston Scientific Corporation B1SX34	R$248.75	R$221.81	-11%
Edwards Lifesciences Corporation EW	$85.88	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2407 (2407) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$14.30 versus a price of HK$5.00 — about +186% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2407?

Our model-based fair value for 2407 is HK$14.30 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$5.00.

What is the quality score of 2407?

2407 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2407 (2407)?

2407 reported trailing-twelve-month revenue of about HK$1.4B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2407?

The net profit margin of 2407 is about 7.0%, meaning it keeps roughly 7.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.